tibolone + estradiol-norethisterone
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sexual Dysfunction
Conditions
Sexual Dysfunction
Trial Timeline
Mar 23, 2004 → Nov 15, 2005
NCT ID
NCT00413764About tibolone + estradiol-norethisterone
tibolone + estradiol-norethisterone is a phase 3 stage product being developed by Organon for Sexual Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00413764. Target conditions include Sexual Dysfunction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00413764 | Phase 3 | Completed |
Competing Products
18 competing products in Sexual Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dapoxetine | Johnson & Johnson | Phase 3 | 77 |
| Gardasil Vaccine | Merck | Pre-clinical | 23 |
| sildenafil | Pfizer | Approved | 84 |
| sildenafil | Pfizer | Phase 2 | 51 |
| CP-866,087 + CP-866,087 + CP-866,087 + Placebo | Pfizer | Phase 2 | 51 |
| PF-00446687 + Placebo | Pfizer | Phase 2 | 51 |
| Bremelanotide | Pfizer | Phase 2 | 51 |
| Sildenafil 100 mg + Placebo | Pfizer | Phase 2 | 51 |
| Alfuzosin | Sanofi | Approved | 84 |
| AVANAFIL + placebo | Sanofi | Phase 3 | 76 |
| Levitra (Vardenafil, BAY38-9456) + Placebo | Bayer | Approved | 82 |
| Placebo + 0.5 mgTestosterone + 10 mg Buspirone | Brain Biotech | Phase 2 | 44 |
| Placebo + Testosterone + Buspirone hydrochloride | Brain Biotech | Phase 2 | 44 |
| Placebo + Sildenafil + Testosterone | Brain Biotech | Phase 2 | 44 |
| Bremelanotide + Placebo | Palatin Technologies | Phase 3 | 69 |
| bremelanotide | Palatin Technologies | Phase 2 | 44 |
| Bremelanotide | Palatin Technologies | Phase 3 | 69 |
| EVO100 + Placebo | Evofem Biosciences | Phase 3 | 69 |